Integra Lifesciences Holdings Stock Today
| IART Stock | USD 24.54 0.84 3.54% |
Performance7 of 100
| Odds Of DistressLess than 29
|
Integra LifeSciences is selling for under 24.54 as of the 28th of November 2024; that is 3.54 percent up since the beginning of the trading day. The stock's last reported lowest price was 23.62. Integra LifeSciences has about a 29 % chance of experiencing some form of financial distress in the next two years of operation and did not have a very good performance during the last 90 trading days. Note, on July 9, 2024, Representative Josh Gottheimer of US Congress acquired under $15k worth of Integra LifeSciences's common stock.
Business Domain Health Care Equipment & Services | IPO Date 16th of August 1995 | Category Healthcare | Classification Health Care |
Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, and general surgery. Integra LifeSciences Holdings Corporation was incorporated in 1989 and is headquartered in Princeton, New Jersey. The company has 77.16 M outstanding shares of which 4.1 M shares are currently shorted by private and institutional investors with about 4.1 trading days to cover. More on Integra LifeSciences Holdings
Moving together with Integra Stock
Moving against Integra Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Integra Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO President | Jan Witte | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Thematic Ideas | (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Health Care Equipment & Supplies, Health Care Equipment & Services, Health Care, NASDAQ Composite, SP Small-Cap 600, Baby Boomer Prospects, Obamacare Repeal, Health Care, Health Care Equipment & Supplies, Medical Devices, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsIntegra LifeSciences can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Integra LifeSciences' financial leverage. It provides some insight into what part of Integra LifeSciences' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Integra LifeSciences Holdings (IART) is traded on NASDAQ Exchange in USA. It is located in 1100 Campus Road, Princeton, NJ, United States, 08540 and employs 3,946 people. Integra LifeSciences is listed under Health Care Equipment & Supplies category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.89 B. Integra LifeSciences conducts business under Health Care Equipment & Supplies sector and is part of Health Care industry. The entity has 77.16 M outstanding shares of which 4.1 M shares are currently shorted by private and institutional investors with about 4.1 trading days to cover.
Integra LifeSciences Holdings currently holds about 451.52 M in cash with 139.96 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.41.
Check Integra LifeSciences Probability Of Bankruptcy
Ownership AllocationIntegra LifeSciences Holdings has a total of 77.16 Million outstanding shares. The majority of Integra LifeSciences outstanding shares are owned by outside corporations. These institutional investors are usually referred to as non-private investors looking to purchase positions in Integra LifeSciences to benefit from reduced commissions. Consequently, third-party entities are subject to a different set of regulations than regular investors in Integra LifeSciences Holdings. Please pay attention to any change in the institutional holdings of Integra LifeSciences as this could imply that something significant has changed or is about to change at the company. On July 9, 2024, Representative Josh Gottheimer of US Congress acquired under $15k worth of Integra LifeSciences's common stock.
Check Integra Ownership Details
Integra Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Capital Research Global Investors | 2024-09-30 | 1.3 M | |
| Voloridge Investment Management, Llc | 2024-09-30 | 1.1 M | |
| D. E. Shaw & Co Lp | 2024-09-30 | 1 M | |
| Charles Schwab Investment Management Inc | 2024-09-30 | 944.3 K | |
| Neuberger Berman Group Llc | 2024-06-30 | 828.5 K | |
| Northern Trust Corp | 2024-09-30 | 812.3 K | |
| Glenmede Trust Co Na | 2024-09-30 | 727.8 K | |
| Lord, Abbett & Co Llc | 2024-09-30 | 713.3 K | |
| Norges Bank | 2024-06-30 | 686.8 K | |
| Blackrock Inc | 2024-06-30 | 11.3 M | |
| Morgan Stanley - Brokerage Accounts | 2024-06-30 | 11 M |
Integra LifeSciences Historical Income Statement
Integra Stock Against Markets
Integra LifeSciences Corporate Executives
Elected by the shareholders, the Integra LifeSciences' board of directors comprises two types of representatives: Integra LifeSciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Integra. The board's role is to monitor Integra LifeSciences' management team and ensure that shareholders' interests are well served. Integra LifeSciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Integra LifeSciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Lea Knight | Executive CFO | Profile |
Additional Tools for Integra Stock Analysis
When running Integra LifeSciences' price analysis, check to measure Integra LifeSciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Integra LifeSciences is operating at the current time. Most of Integra LifeSciences' value examination focuses on studying past and present price action to predict the probability of Integra LifeSciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Integra LifeSciences' price. Additionally, you may evaluate how the addition of Integra LifeSciences to your portfolios can decrease your overall portfolio volatility.